gene editing
CHOP, Penn Get $14M NIH Grant to Develop Prime-Editing Treatments for Rare Metabolic Diseases
Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.
Editas Medicine Raises $57M by Selling Future Payments From CRISPR Licensing Deal With Vertex Pharma
Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and payments it is owed under an earlier deal with Vertex.
Prime Medicine Pipeline Prioritization, Licensing Deal With BMS to Fund Operations Into 2026
The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.
NTLA-3001 uses CRISPR to insert a healthy copy of the SERPINA1 gene, which is perturbed in alpha-1 antitrypsin deficiency.
YolTech, Salubris Ink Pact to Advance Gene-Editing Therapy for LDL-C-Driven Heart Conditions
In the deal valued at RMB 1.04 billion, Salubris gains exclusive rights to develop and commercialize YOLT-101 in mainland China.
Jul 24, 2024
Mar 1, 2024
Feb 22, 2024